Sophos Biotech

Sophos Biotech is a preclinical-stage biotechnology company based in San Antonio, Texas, focused on developing innovative small molecule therapeutics for cancer. The company's primary mission is to target the MYC oncogene, a master regulator of cell growth and metabolism that is dysregulated in over 70% of human cancers. Despite its clinical importance, MYC has long been considered an "undruggable" target due to its lack of a traditional small-molecule binding pocket. Sophos Biotech utilizes a specialized drug discovery platform to identify and optimize compounds that can effectively inhibit MYC activity. Their lead program, SB-01, is currently undergoing preclinical evaluation for the treatment of both solid tumors and hematological malignancies. By disrupting MYC-driven transcriptional networks, the company aims to provide new treatment options for patients with aggressive and treatment-resistant cancers.